coteauBeta Get App

TLX

Telix Pharmaceuticals Limited
$10.08
-9.68% Oct 21 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-41%-26%-11%+4%+19%Oct 2025Oct 2026Apr 2026
TLXSPY
1W
-5.4%
1M
-10.9%
3M
-2.3%
6M
-2.4%
YTD
+34.6%
1Y
-7.7%

Live chart

Loading live chart…

What they do

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC).

Healthcare · Biotechnology

For information only · Important disclosures

Grades vs sector

No sector grades for TLX yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 5 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 Coteau Long Book
Not in the current book

News

More news
TLX, Ekalia Team Up to Boost US Production of Isotope for Cancer Therapies
MT Newswires · Oct 19

Key stats

Market value$3.4B
P/E (last 12 months)100.8
P/E (next 12 months, estimated)-375.0
52-week range$6.28 – $13.11
Revenue growth (latest quarter vs a year ago)+22.3%
Dividend yieldNo dividend
Analyst consensusStrong Buy (5)
Average analyst price target$20.83 (+107%)
Valuation and fundamentals

Valuation & fundamentals

No US-GAAP 10-K/10-Q financials in SEC data (foreign filers report on Form 20-F, often under IFRS).

Earnings

Next report: –
No EPS history available.
Rating changes
Reiterated
2026-10-21 · Wedbush reiterated Outperform on TLX
Reiterated
2026-09-25 · HC Wainwright & Co. reiterated Buy on TLX
Reiterated
2026-09-23 · Wedbush reiterated Outperform on TLX
Reiterated
2026-09-15 · HC Wainwright & Co. reiterated Buy on TLX
Reiterated
2026-09-14 · Wedbush reiterated Outperform on TLX
Reiterated
2026-09-02 · HC Wainwright & Co. reiterated Buy on TLX

Third-party analyst actions, not Coteau's views. All rating changes

Stats refreshed 2026-10-21 13:44:35 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Free. Not investment advice. Unsubscribe anytime.

coteau

Independent research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksTermsPrivacyData statusSend feedback
Beta 0.9 · Oct 21, 2026